Decisions of the Annual General Meeting of Biohit Oyj

Biohit Oyj April 8, 2013 at 5.45 P.M. local time

The Annual General Meeting (AGM) of Biohit Oyj held on Monday April 8, 2013 approved the financial statements of the parent company and the consolidated financial statements, and discharged the members of the Board of Directors and the President and CEO from liability for the financial year 2012.
 

Distribution of dividends

In accordance with the proposal by the Board of Directors, the AGM decided that the loss for the financial period ended on December 31, 2012 will be recorded in the profit and loss account.

In accordance with the proposal by the Board of Directors, the AGM decided that on the basis of the financial statements for the financial period ended on December 31, 2012, a dividend of EUR 0.4964 per each A share and EUR 0.4998 for each B share be paid. Dividend will be paid to shareholders recorded in the company's shareholder register on the matching day, April 11, 2013. Dividend will be paid out on April 18, 2013.

In accordance with the proposal of the Board of Directors, the AGM decided that on the basis of the financial statements for the financial period ended on December 31, 2012, funds from the invested non-restricted equity fund be distributed to shareholders as a capital repayment, with the capital repaid amounting to EUR 0.237 for each A and B share. Capital will be repaid to shareholders recorded in the company's shareholder register on the repayment day on April 11, 2013. Capital repayment will be made on April 18, 2013.
 

Members of the Board of Directors

The AGM decided that the number of members of the Board of Directors would be five (5). Furthermore, that the following Board members re-elected until the end of the next AGM:  Professor Osmo Suovaniemi, Professor Mikko Salaspuro, Commercial Counselor Eero Lehti, M.Sc.Eng. Seppo Luode, and as a new board member CEO Franco Aiolfi.

Additionally, the AGM decided that the chairman of the Board of Directors would be paid a monthly fee of EUR 1,600 and the ordinary members would be paid a monthly fee of EUR 1,500.
 

Auditors

The AGM elected authorised public accountants Ernst & Young Oy as the company’s auditors, with APA Erkka Talvinko as the head auditor, until the end of the next AGM.

All decisions of the AGM were made unanimously. The minutes of the AGM will be available for review by shareholders by April 22, 2013 on the company’s website (www.biohithealthcare.com / investors) and at the corporate headquarters of Biohit, located at Laippatie 1, 00880 Helsinki.
 

Additional information:

CEO Semi Korpela, Biohit Oyj
Tel. +358 9 773 861
semi.korpela@biohit.fi
www.biohithealthcare.com

Biohit in brief

Biohit Oyj is a Finnish biotechnology company operating globally that was established in 1988. Biohit's mission is "Innovating for Health". The purpose of the company is to take social responsibility and produce innovation, new technologies and analysis systems for use in medicine, research institutions and industry, helping to promote research and diagnostics and to improve the quality of life of people by means of preventing disease, human suffering and financial loss. We are committed to social responsibility and it is our duty to spread knowledge about the Group 1 human carcinogen, acetaldehyde, and innovate and develop the marketing and availability of our products and services. Biohit is headquartered in Helsinki and its subsidiaries are located in China and the United Kingdom. Since 1999, Biohit's Series B shares (BIOBV) have been listed in the NASDAQ OMX Helsinki Oy Small cap/Healthcare sector.